A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

Inclusion criteria

• Aged 18-75 years
• ECOG performance status score of 0 or 1;
• Histopathologically confirmed advanced or metastatic non-small cell lung cancer;
• Participants must provide archived or fresh tumor tissue;
• Participants must have experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease;
• At least one measurable lesion according to RECIST v1.1 criteria;
• Expected survival ≥3 months;
• Adequate organ function;

Exclusion criteria

• Central nervous system metastasis or meningeal metastasis with clinical symptoms
• History of or concurrent other malignancies;
• Untreated spinal cord compression ;
• Uncontrolled tumor-related pain;
• Adverse events (AEs) from prior therapy not recovered to CTCAE Grade ≤1;
• History of interstitial lung disease;
• Severe cardiovascular/cerebrovascular diseases;